Deutsche Bank
ENTA icon

Deutsche Bank’s Enanta Pharmaceuticals ENTA Stock Holding History

Deutsche Bank’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$245K Sell
19,395
-4,712
-20% -$63.2K ﹤0.01% 2922
2025
Q4 		$380K Buy
24,107
+1,055
+5% +$13.4K ﹤0.01% 2705
2025
Q3 		$276K Buy
+23,052
New +$184K ﹤0.01% 2897
2024
Q4 		– Sell
-10,432
Closed -$108K – 3634
2024
Q3 		$108K Buy
10,432
+4,091
+65% +$53.5K ﹤0.01% 3195
2024
Q2 		$82.2K Sell
6,341
-4,366
-41% -$58.9K ﹤0.01% 3177
2024
Q1 		$187K Buy
10,707
+531
+5% +$7.03K ﹤0.01% 2857
2023
Q4 		$95.8K Sell
10,176
-189
-2% -$1.76K ﹤0.01% 3236
2023
Q3 		$116K Buy
10,365
+1,383
+15% +$22.3K ﹤0.01% 3094
2023
Q2 		$192K Sell
8,982
-5,952
-40% -$175K ﹤0.01% 2897
2023
Q1 		$604K Buy
14,934
+4,196
+39% +$200K ﹤0.01% 2384
2022
Q4 		$500K Buy
10,738
+2,204
+26% +$100K ﹤0.01% 2448
2022
Q3 		$443K Sell
8,534
-1,273
-13% -$74.4K ﹤0.01% 2442
2022
Q2 		$463K Sell
9,807
-1,140
-10% -$61.9K ﹤0.01% 2649
2022
Q1 		$779K Sell
10,947
-31,192
-74% -$2.03M ﹤0.01% 2499
2021
Q4 		$3.15M Sell
42,139
-24,288
-37% -$1.91M ﹤0.01% 1708
2021
Q3 		$3.77M Buy
66,427
+2,816
+4% +$139K ﹤0.01% 1681
2021
Q2 		$2.8M Sell
63,611
-18,726
-23% -$917K ﹤0.01% 1925
2021
Q1 		$4.06M Buy
82,337
+12,712
+18% +$634K ﹤0.01% 1671
2020
Q4 		$2.93M Buy
69,625
+57,968
+497% +$2.55M ﹤0.01% 1668
2020
Q3 		$534K Sell
11,657
-130,398
-92% -$6.32M ﹤0.01% 2602
2020
Q2 		$7.13M Sell
142,055
-120,017
-46% -$6.21M 0.01% 1120
2020
Q1 		$13.5M Buy
262,072
+134,209
+105% +$7.15M 0.01% 806
2019
Q4 		$7.9M Buy
127,863
+121,491
+1,907% +$7.53M 0.01% 1212
2019
Q3 		$381K Sell
6,372
-1,926
-23% -$143K ﹤0.01% 2814
2019
Q2 		$697K Sell
8,298
-51,640
-86% -$4.65M ﹤0.01% 3078
2019
Q1 		$5.72M Sell
59,938
-16,898
-22% -$1.52M ﹤0.01% 1770
2018
Q4 		$5.44M Sell
76,836
-14,903
-16% -$1.14M ﹤0.01% 1714
2018
Q3 		$7.84M Buy
91,739
+26,993
+42% +$2.7M ﹤0.01% 1854
2018
Q2 		$7.5M Sell
64,746
-17,260
-21% -$1.72M ﹤0.01% 1979
2018
Q1 		$6.63M Buy
82,006
+44,507
+119% +$3.43M ﹤0.01% 1975
2017
Q4 		$2.2M Buy
37,499
+19,102
+104% +$957K ﹤0.01% 2657
2017
Q3 		$859K Sell
18,397
-410
-2% -$16.5K ﹤0.01% 3119
2017
Q2 		$676K Sell
18,807
-32,833
-64% -$1.05M ﹤0.01% 3274
2017
Q1 		$1.59M Sell
51,640
-12,804
-20% -$399K ﹤0.01% 2389
2016
Q4 		$2.16M Sell
64,444
-104,790
-62% -$3M ﹤0.01% 2210
2016
Q3 		$4.5M Buy
169,234
+43,655
+35% +$1.01M ﹤0.01% 1801
2016
Q2 		$2.77M Buy
125,579
+59,541
+90% +$1.56M ﹤0.01% 2159
2016
Q1 		$1.94M Sell
66,038
-67,610
-51% -$1.88M ﹤0.01% 2388
2015
Q4 		$4.41M Buy
133,648
+115,880
+652% +$3.78M ﹤0.01% 1876
2015
Q3 		$641K Buy
17,768
+3,554
+25% +$153K ﹤0.01% 3224
2015
Q2 		$639K Buy
14,214
+5,052
+55% +$197K ﹤0.01% 3256
2015
Q1 		$279K Sell
9,162
-69,572
-88% -$2.71M ﹤0.01% 3616
2014
Q4 		$4M Buy
78,734
+1,567
+2% +$70.2K ﹤0.01% 2136
2014
Q3 		$3.05M Buy
77,167
+48,711
+171% +$1.94M ﹤0.01% 2204
2014
Q2 		$1.23M Buy
28,456
+9,661
+51% +$369K ﹤0.01% 2798
2014
Q1 		$751K Buy
18,795
+16,104
+598% +$585K ﹤0.01% 3061
2013
Q4 		$73K Sell
2,691
-14,630
-84% -$355K ﹤0.01% 4189
2013
Q3 		$396K Buy
17,321
+522
+3% +$9.97K ﹤0.01% 3682
2013
Q2 		$296K Buy
+16,799
New +$328K ﹤0.01% 3538

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Deutsche Bank's ENTA Position: Q1 2026 in Review

Deutsche Bank reduced its Enanta Pharmaceuticals (ENTA) stake by 20% in Q1 2026, selling an estimated $63.2K and leaving 19,395 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #2922.

Deutsche Bank first reported a position in ENTA in Q2 2013 and has held it in 49 quarters since. The position peaked at $13.5M in Q1 2020. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Deutsche Bank held 19,395 shares of Enanta Pharmaceuticals worth $245K as of Q1 2026.
  • Deutsche Bank sold 4,712 Enanta Pharmaceuticals shares in Q1 2026, an estimated $63.2K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2922 holding.
  • Deutsche Bank first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Deutsche Bank's Enanta Pharmaceuticals position peaked at $13.5M in Q1 2020.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.